Overall, this work identifies COX-1 and its product TXA2 as potential pharmacological targets to inhibit the intravascular phase of metastasis, consistent with the use of low- to medium-dose aspirin as adjuvant therapy for cancer patients. The gene discussed is PTGS1; the disease is cancer.